Xerostomia-optimised IMRT Versus Standard IMRT in NPC
This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients
- EligibilityCriteria: Inclusion Criteria:  Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II/III); All genders, range from 18-70 years old; ECOG score 0-1; Clinical stage I-IVa (AJCC/UICC 8th); Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy); No contraindications to chemotherapy or radiotherapy; Adequate organ function: white blood cell count ≥ 4×109/L, neutrophile granulocyte count ≥ 1.5×109/L, hemoglobin ≥ 90g/L, platelet count ≥ 100×109/L; alanine aminotransferase or aspartate aminotransferase < 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula); Sign the consent form.  Exclusion Criteria:  Level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 3cm in level II ;  -≥4 nodal regions of ipsilateral neck involvement;  Radiologically suspicious or confirmed involvement in level II area between skull base and the lateral process of C1; Parotid lymph node and/or parotid gland involvement; History of parotid disease or surgery; Previous malignancy or other concomitant malignant disease; Pregnancy or lactation. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult